Navigation Links
Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma
Date:8/29/2014

Boston, MA, San Antonio, TX (PRWEB) August 29, 2014

Intrinsic Imaging, an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant imaging core lab, announced today that it has been awarded an international Phase II clinical trial to assess a new treatment for patients with non-Hodgkin’s lymphoma.

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and charter development, site qualification, site training and management, image transfer, blinding and processing as well as the specialized radiologic review of images acquired using positron emission tomography coupled with computed tomography (PET/CT), or PET coupled with magnetic resonance imaging (PET/MRI).

Intrinsic Imaging’s more than sixty board-certified radiologists have fellowship training in all subspecialty therapeutic areas including Oncology. The Oncology team consists of 12 full-time board-certified, fellowship trained radiologists all of whom have significant expertise in the evaluation of many cancers including but not limited to breast, cervical, colorectal, gastric, head and neck, lung, lymphoma, melanoma, ovarian, prostate, renal and thyroid.

“At Intrinsic Imaging, we are able to provide our wealth of oncology expertise to the design and management of clinical trials and to the determination of drug efficacy and/or disease progression,” said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging. “Of the more than 1 million images reviewed annually by Intrinsic Imaging radiologists, 400,000 images are oncology related.”

Non-Hodgkin's lymphoma is cancer that originates in the lymphatic system. According to their April 2014 report, the Leukemia and Lymphoma Society estimate there are 558,340 people in the United States who are living with the disease or are in remission and another 70,800 new cases of non-Hodgkin’s lymphoma are expected to be diagnosed. Non-Hodgkin's lymphoma is the seventh most common cause of cancer related deaths in the United States.

About Intrinsic Imaging LLC
Located in Bolton, Massachusetts and San Antonio, Texas, Intrinsic Imaging is an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 medical imaging core lab specializing in providing imaging core lab services for clinical trials. With its team of more than sixty board-certified diagnostic radiologists, robust and scalable clinical imaging technologies and our ISO certified and registered quality management systems, Intrinsic Imaging is ideally positioned to provide unprecedented imaging core lab services around the world. For more information, please visit http://www.IntrinsicCRO.com.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12127480.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Quantitative Profiling of the Intrinsic Pathway of Apoptosis in Tumor Tissue Using Myriad RBM’s Multiplex ApoptosisMAP™, a New Biomarker Webinar by Xtalks
2. Intrinsically disordered proteins: A conversation with Rohit Pappu
3. A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy
4. JH Technologies Brings an Expanded Level of Microscope and Imaging Expertise to Industrial Customers in Southern California
5. ChemImage Presents Latest Developments for in vitro Detection of Cancer Using Raman Chemical Imaging at International Conference on Raman Spectroscopy
6. Global Medical Imaging Reagents (Nanoparticles, Fluorescent Proteins, Fluorescent Dyes and Probes, Radiopharmaceuticals and Quantum Dots) Market - Forecast to 2019
7. Fastec Imaging Introduces the First High Speed Camcorder
8. Latest Technologies for Life-saving Applications on the Program at SPIE Medical Imaging
9. Founders Fund Backs Nanotronics Imaging
10. Smart Imaging Technologies and InvitroCue Team Up to Bring Digital Pathology to Asia
11. New venue, new conference, new courses, new technologies for Electronic Imaging 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... and HAMILTON, Bermuda , Feb. ... ADXS ) and SELLAS Life ... on developing cancer immunotherapies, today announced that Advaxis ... novel cancer immunotherapy agent using Advaxis, proprietary ... WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S). ...
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as ... private label organic services. , The first organic product is Organic 18 Percent Layer ... Dynamite Marketing, which owns the facility. , Catalyst already has received the Safe ...
(Date:2/24/2017)... ... February 24, 2017 , ... A ... safely completed in an ambulatory surgery center (ASC) with satisfactory clinical and patient-reported ... two-year TDR studies. , Jake Lubinski, president of AxioMed, commented on the ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
Breaking Biology Technology:
(Date:1/26/2017)... 2017  Crossmatch, a leading provider of security and ... at combatting fraud, waste and abuse in assistance operations ... Action on Disaster Relief conference in Panama ... agencies and foreign assistance organizations throughout Latin ... are a largely unacknowledged problem in the foreign assistance ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements of ... (IAM) lifecycle is comprised of a comprehensive set ... purpose of maintaining digital identities and providing a ... applications. There are significant number of programs opted ... to time by optimizing processes and changing policies. ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds ... baby,s sock that monitors vital signs and alerts ... an infant,s oxygen saturation level drops. But pediatric ... alarm to parents, with no evidence of medical ... devices are marketed aggressively to parents of healthy ...
Breaking Biology News(10 mins):